| Literature DB >> 30737883 |
You Lan1, Mao Zhou1, Zijuan Jian1, Qun Yan1, Siyi Wang1, Wenen Liu1.
Abstract
BACKGROUND: The emerging pks-positive (pks+ ) strains have aroused great public concern recently. Colibactin, encoded by pks gene cluster, has been reported to be involved in DNA damage and increased virulence. Little is known about its prevalence among Klebsiella pneumoniae-induced bloodstream infections (BSIs). Therefore, the aim of this study was to investigate the prevalence of pks gene cluster, and molecular and clinical characteristics of K pneumoniae-induced BSIs.Entities:
Keywords: zzm321990Klebsiella pneumoniaezzm321990; bloodstream infections; hypervirulent; molecular characteristic; pks gene cluster
Mesh:
Substances:
Year: 2019 PMID: 30737883 PMCID: PMC6528554 DOI: 10.1002/jcla.22838
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
Primers used in this study
| Primer name | DNA sequence (5′‐3′) | Amplicon size (bp) |
|---|---|---|
| Capsular serotypes | ||
| K1 | F: GGTGCTCTTTACATCATTGC | 1283 |
| R:GCAATGGCCATTTGCGTTAG | ||
| K2 | F:GACCCGATATTCATACTTGACAGAG | 641 |
| R:CCTGAAGTAAAATCGTAAATAGATGGC | ||
| K5 | F:TGGTAGTGATGCTCGCGA | 741 |
| R:CCTGAACCCACCCCAATC | ||
| K20 | F:CGGTGCTACAGTGCATCATT | 280 |
| R:GTTATACGATGCTCAGTCGC | ||
| K54 | F:CATTAGCTCAGTGGTTGGCT | 881 |
| R:GCTTGACAAACACCATAGCAG | ||
| K57 | F:CTCAGGGCTAGAAGTGTCAT | 1037 |
| R:CACTAACCCAGAAAGTCGAG | ||
|
| F:GTGCCGCGAGCGCTTTCTATCTTGGTA TTCC | 580 |
| R:GAGAGCCACTGGTTCCAGAA[C/T]TT[C/G]ACCGC | ||
| Virulence genes | ||
|
| F:CATAAGAGTATTGGTTGACAG | 461 |
| R:CTTGCATGAGCCATCTTTCA | ||
|
| F: GGTTGGKTCAGCAATCGTA | 169 |
| R:ACTATTCCGCCAACTTTTGC | ||
|
| F:AAGCTATCGCTGTACTTCCGGCA | 340 |
| R:GGCGTTGGCGCTCAGATAGG | ||
|
| F:CATTACGCACCTTTGTCAGC | 764 |
| R:GAATGTGTCGGCGATCAGCTT | ||
|
| F:GACGGAAACAGCACGGTAAA | 242 |
| R:GAGCATAATAAGGCGAAAGA | ||
|
| F:GGCCTTTGTCCAGAGCTACG | 638 |
| R:GGGTCTGGCGCAGAGTATGC | ||
|
| F:GCATAGGCGGATACGAACAT | 556 |
| R:CACAGGGCAATTGCTTACCT | ||
|
| ||
|
| F:CTAGATTATCCGTGGCGATTC | 1311 |
| R:CAGATACACAGATACCATTCA | ||
|
| F:GATTTGGATACTGGCGATAACCG | 579 |
| R:CCATTTCCCGTTTGAGCACAC | ||
|
| F:GTTTTGCTCGCCAGATAGTCATTC | 733 |
| R:CAGTTCGGGTATGTGTGGAAGG | ||
|
| F:CTTGTATAGTTACACAACTATTTC | 821 |
| R:TTATCCTGTTAGCTTTCGTTC | ||
Capsular types and virulence gene distribution of pks‐positive and pks‐negative K pneumoniaebloodstream isolates
| Virulence factors |
|
|
|
|---|---|---|---|
| Capsular types | |||
| K1 | 9 (17.6%) | 0 | 0.000 |
| K2 | 7 (13.7%) | 15 (10.8%) | 0.575 |
| K5 | 0 | 1 (0.7%) | 1.000 |
| K20 | 2 (3.9%) | 0 | 0.071 |
| K54 | 2 (3.9%) | 0 | 0.071 |
| K57 | 6 (11.8%) | 1 (0.7%) | 0.000 |
| Virulence genes | |||
|
| 30 (58.8%) | 21 (15.1%) | 0.000 |
|
| 20 (39.2%) | 4 (2.8%) | 0.000 |
|
| 51 (100%) | 125 (89.9%) | 0.019 |
|
| 38 (74.5%) | 52 (37.4%) | 0.000 |
|
| 41 (80.4%) | 65 (47.0%) | 0.000 |
|
| 21 (41.2%) | 25 (18.0%) | 0.001 |
|
| 32 (62.7%) | 23 (16.5%) | 0.000 |
| HvKP | 28 (54.9%) | 13 (9.4%) | 0.000 |
A P value < 0.05 was considered to be statistically significant.
Antimicrobial resistance of pks‐positive and pks‐negative K pneumoniaebloodstream isolates
| Antimicrobial agent |
|
|
|
|---|---|---|---|
| Ampicillin‐sulbactam | 20 (39.2%) | 71 (51.1%) | 0.097 |
| Piperacillin‐tazobactam | 8 (15.7%) | 46 (33.1%) | 0.013 |
| Cefoperazone‐sulbactam | 10 (19.6%) | 51 (36.7%) | 0.017 |
| Cefazolin | 19 (37.3%) | 79 (56.8%) | 0.008 |
| Cefuroxime | 17 (33.3%) | 48 (34.5%) | 0.766 |
| Ceftazidime | 14 (27.4%) | 52 (37.4%) | 0.196 |
| Ceftriaxone | 18 (35.3%) | 71 (51.1%) | 0.032 |
| Cefepime | 20 (39.2%) | 59 (42.4%) | 0.508 |
| Cefotan | 8 (15.7%) | 37 (26.6%) | 0.093 |
| Aztreonam | 15 (29.4%) | 70 (50.4%) | 0.005 |
| Ertapenem | 8 (15.7%) | 49 (35.2%) | 0.006 |
| Meropenem | 7 (13.7%) | 45 (32.4%) | 0.007 |
| Imipenem | 9 (17.6%) | 47 (33.8%) | 0.022 |
| Tobramycin | 10 (19.6%) | 35 (25.2%) | 0.363 |
| Amikacin | 7 (13.7%) | 33 (23.7%) | 0.110 |
| Gentamicin | 13 (25.5%) | 48 (34.5%) | 0.186 |
| Levofloxacin | 8 (15.7%) | 47 (33.8%) | 0.010 |
| Ciprofloxacin | 8 (15.7%) | 52 (37.4%) | 0.003 |
| Trimethoprim‐sulfamethoxazole | 11 (21.6%) | 48 (34.5%) | 0.065 |
| Furantoin | 13 (26.0%) | 62 (47.0%) | 0.010 |
A P value < 0.05 was considered to be statistically significant.
Clinical characteristics of pks‐positive and pks‐negative K pneumoniae‐induced bloodstream infections
| Characteristics |
|
|
|
|---|---|---|---|
| Age | 54.3 ± 19.8 | 37.7 ± 26.5 | 0.099 |
| Female | 14 (27.5%) | 22 (15.8%) | 0.841 |
| Acquisition | |||
| Community‐acquired | 31 (60.8%) | 59 (42.4%) | 0.000 |
| Hospital‐acquired | 20 (39.2%) | 80 (57.6%) | 0.000 |
| Underlying condition | |||
| Diabetes mellitus | 15 (29.4%) | 19 (13.6%) | 0.012 |
| Hypertension | 17 (33.3%) | 19 (13.7%) | 0.002 |
| Biliary tract disease | 3 (5.9%) | 17 (12.2%) | 0.206 |
| Liver cirrhosis | 4 (7.8%) | 4 (2.9%) | 0.131 |
| Pulmonary infection | 7 (13.7%) | 13 (9.3%) | 0.384 |
| Hematologic diseases | 7 (13.7%) | 17 (12.2%) | 0.783 |
| Cancer | 8 (15.7%) | 23 (16.5%) | 0.846 |
| Surgery within 30 d | 19 (37.3%) | 44 (31.7%) | 0.467 |
| Chemotherapy within 7 d | 8 (15.7%) | 21 (15.1%) | 0.704 |
| Primary site | |||
| Biliary tract | 2 (3.9%) | 10 (7.2%) | 0.411 |
| Respiratory tract | 29 (56.9%) | 93 (65.5%) | 0.276 |
| Urinary tract | 5 (9.8%) | 10 (7.2%) | 0.554 |
| Intra‐abdomen | 5 (9.8%) | 13 (9.4%) | 0.925 |
| Brain | 2 (3.9%) | 3 (2.2%) | 0.182 |
| Liver abscess | 3 (5.9%) | 0 | 0.573 |
| Laboratory data (mean ± SD) | |||
| WBC count, ×109/L | 8.7 ± 6.6 | 10.9 ± 8.9 | 0.746 |
| RBC count, ×1012/L | 3.2 ± 0.9 | 3.1 ± 0.8 | 0.051 |
| HB, g/L | 95.4 ± 28.5 | 97.4 ± 26.2 | 0.272 |
| PLT, ×109/L | 119.4 ± 97.4 | 105.0 ± 92.4 | 0.876 |
| NEUT count, ×109/L | 7.5 ± 6.3 | 7.9 ± 7.6 | 0.952 |
| LY count, ×109/L | 0.6 ± 0.6 | 1.6 ± 1.5 | 0.016 |
HB, hemoglobin; LY, lymphocyte; NEUT, neutrophile granulocyte; PLT, platelet; RBC, red blood cell; WBC, white blood cell.
A P value <0.05 was considered to be statistically significant.